{"url":"https://lda.senate.gov/api/v1/filings/d15869e2-bfcd-4dfa-8a89-eab28aa0fa78/","filing_uuid":"d15869e2-bfcd-4dfa-8a89-eab28aa0fa78","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2012,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/d15869e2-bfcd-4dfa-8a89-eab28aa0fa78/print/","filing_document_content_type":"text/html","income":"30000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Denny Miller, President","dt_posted":"2012-10-15T13:55:42.557000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"400 N Capitol St, NW Suite 363","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":25328,"url":"https://lda.senate.gov/api/v1/registrants/25328/","house_registrant_id":30761,"name":"DENNY MILLER ASSOCIATES","description":"Lobbying, consulting and government relations","address_1":"400 N Capitol St, Ste 363","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MELISSA BROWN","contact_telephone":"+1 202-783-0280","dt_updated":"2022-04-06T16:06:34.952708-04:00"},"client":{"id":133018,"url":"https://lda.senate.gov/api/v1/clients/133018/","client_id":48,"name":"CELL THERAPEUTICS","general_description":null,"client_government_entity":false,"client_self_select":null,"state":"WA","state_display":"Washington","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-07-30"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"European Union approval of US cancer drugs.","foreign_entity_issues":"Italian Embassy.","lobbyists":[{"lobbyist":{"id":50262,"prefix":null,"prefix_display":null,"first_name":"JUDSON","nickname":null,"middle_name":null,"last_name":"GREIF","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":12626,"prefix":"ms","prefix_display":"MS.","first_name":"SANDRA","nickname":null,"middle_name":null,"last_name":"MATHIESEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13388,"prefix":null,"prefix_display":null,"first_name":"WILL","nickname":null,"middle_name":null,"last_name":"STONE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"S. 3187, Food and Drug Administration Safety and Innovation Act of 2012, provisions relating to the approval of new drugs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":50262,"prefix":null,"prefix_display":null,"first_name":"JUDSON","nickname":null,"middle_name":null,"last_name":"GREIF","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":12626,"prefix":"ms","prefix_display":"MS.","first_name":"SANDRA","nickname":null,"middle_name":null,"last_name":"MATHIESEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}